Studerus, Erich
Lade...
E-Mail-Adresse
Geburtsdatum
Projekt
Organisationseinheiten
Berufsbeschreibung
Nachname
Studerus
Vorname
Erich
Name
Erich Studerus
3 Ergebnisse
Suchergebnisse
Gerade angezeigt 1 - 3 von 3
Publikation Subjective long-term emotional and social effects of recreational MDMA use: the role of setting and intentions(Springer, 2024) Elmer, Timon; Vannoy, Tanya K.; Studerus, Erich; Lyubomirsky, SonjaMDMA is a recreational drug commonly used to enhance euphoria, but it is also used in non-party settings with self-insight or social connection intentions. Yet, little is known about whether distinct consumer groups are formed based on consumption setting and intention. We aimed to characterize different types of recreational MDMA users based on consumption setting and intentions, and to examine their differences in perceptions of long-term social-emotional effects of MDMA use. We analyzed self-reports of 766 individuals (ages 18–61, mostly from Western countries), reporting on their MDMA consumption habits and perceived effects. We used a K-medoids clustering algorithm to identify distinct types of consumption settings and intentions. We identified three setting types – party settings with friends (N = 388), private home settings (N = 132), mixed settings (N = 246) – and three intention types – euphoria and energy (N = 302), self-insight (N = 219), mixed intentions (N = 245). Members of the self-insight and mixed intentions clusters reported considerably more long-term socio-emotional benefits than members of the euphoria and energy cluster. No differences were observed between the setting clusters. In this particular sample, more long-term benefits than harms were reported. Our findings suggest that the long-term social-emotional benefits of MDMA are associated with whether users seek self-insight or have mixed intentions.01A - Beitrag in wissenschaftlicher ZeitschriftPublikation Influence of cannabis use on incidence of psychosis in people at clinical high risk(Wiley, 2023) Chester, Lucy Ann; Valmaggia, Lucia; Kempton, Matthew; Chesney, Edward; Oliver, Dominic; Hedges, Emily; Klatsa, Elise; Stahl, Daniel; van der Gaag, Mark; de Haan, Lieuwe; Nelson, Barnaby; McGorry, Patrick; Amminger, G. Paul; Riecher-Rössler, Anita; Studerus, Erich; Bressan, Rodrigo; Barrantes-Vidal, Neus; Krebs, Marie-Odile; Glenthøj, Birte; Nordentoft, Merete; Ruhrmann, Stephan; Sachs, Gabriele; McGuire, PhilipAims Evidence for case–control studies suggests that cannabis use is a risk factor for the development of psychosis. However, there have been limited prospective studies and the direction of this association remains controversial. The primary aim of the present study was to examine the association between cannabis use and the incidence of psychotic disorders in people at clinical high risk of psychosis. Secondary aims were to assess associations between cannabis use and the persistence of psychotic symptoms, and with functional outcome. Methods Current and previous cannabis use were assessed in individuals at clinical high risk of psychosis (n = 334) and healthy controls (n = 67), using a modified version of the Cannabis Experience Questionnaire. Participants were assessed at baseline and followed up for 2 years. Transition to psychosis and persistence of psychotic symptoms were assessed using the Comprehensive Assessment of At-Risk Mental States criteria. Level of functioning at follow up was assessed using the Global Assessment of Functioning disability scale. Results During follow up, 16.2% of the clinical high-risk sample developed psychosis. Of those who did not become psychotic, 51.4% had persistent symptoms and 48.6% were in remission. There was no significant association between any measure of cannabis use at baseline and either transition to psychosis, the persistence of symptoms, or functional outcome. Conclusions These findings contrast with epidemiological data that suggest that cannabis use increases the risk of psychotic disorder.01A - Beitrag in wissenschaftlicher ZeitschriftPublikation Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies(SAGE, 2021) Studerus, Erich; Vizeli, Patrick; Harder, Samuel; Ley, Laura; Liechti, Matthias EBackground: 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") is used both recreationally and therapeutically. Little is known about the factors influencing inter- and intra-individual differences in the acute response to MDMA. Effects of other psychoactive substances have been shown to be critically influenced by personality traits and mood state before intake. Methods: We pooled data from 10 randomized, double-blind, placebo-controlled, cross-over studies performed in the same laboratory in 194 healthy subjects receiving doses of 75 or 125mg of MDMA. We investigated the influence of drug dose, body weight, sex, age, drug pre-experience, genetics, personality and mental state before drug intake on the acute physiological and psychological response to MDMA. Results: In univariable analyses, the MDMA plasma concentration was the strongest predictor for most outcome variables. When adjusting for dose per body weight, we found that (a) a higher activity of the enzyme CYP2D6 predicted lower MDMA plasma concentration, (b) a higher score in the personality trait "openness to experience" predicted more perceived "closeness", a stronger decrease in "general inactivation", and higher scores in the 5D-ASC (5 Dimensions of Altered States of Consciousness Questionnaire) scales "oceanic boundlessness" and "visionary restructuralization", and (c) subjects with high "neuroticism" or trait anxiety were more likely to have unpleasant and/or anxious reactions. Conclusions: Although MDMA plasma concentration was the strongest predictor, several personality traits and mood state variables additionally explained variance in the response to MDMA. The results confirm that both pharmacological and non-pharmacological variables influence the response to MDMA. These findings may be relevant for the therapeutic use of MDMA.01A - Beitrag in wissenschaftlicher Zeitschrift